Skin Analytics secured a Class III CE mark for DERM, allowing DERM to autonomously discharge benign skin cancer cases from its clinical pathways.

Skin Analytics is on a mission to help more people survive skin cancer. Our DERM AI technology - the world's only Class III CE-marked AI medical device for skin cancer assessment, is already deployed across 24 NHS hospitals and through our partnership with Bupa. DERM helps healthcare systems build robust skin cancer pathways. Since its first NHS deployment in 2020, DERM has assessed more than 230,000 patients and identified over 20,000 cancers. Some things we’re a little bit proud of: 🚀We’ve worked with the NHS since 2020 and DERM is currently deployed across 25 primary and secondary care organisations 🥇We’re the first AI skin cancer pathway within the NHS ✅ DERM is recommended by the National Institute for Health and Care Excellence (NICE) ✅DERM is the only Class III CE marked AI as a Medical Device for skin cancer 🤯DERM is used in pathways that have seen over 230,000 NHS patients and identified more than 20,000 cancers 💪We’ve helped NHS organisations avoid up to 95% of face-to-face appointments in secondary care 🤳We provide Bupa and Vitality's remote skin assessment service ❤️Everything we do is in pursuit of better patients outcomes that are sustainable for health systems, globally